PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

Fast Track, page-11

  1. 253 Posts.
    lightbulb Created with Sketch. 33
    I saw it on channel 9 hence my question regarding the differences between the two treatments. If SCT has no effect surely that is a great advantage for IPPS over SCT, right ?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.